Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Information source: University of Pittsburgh
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacteremia; AmpC Beta-lactamase
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s):
David L Paterson, MD, Principal Investigator, Affiliation: University of Pitttsburgh
Yohei Doi, MD, Principal Investigator, Affiliation: University of Pittsburgh
Summary
Nosocomial bloodstream infections are important causes of morbidity and mortality caused by
AmpC beta-lactamase-producing Enterobacteriaceae. The information collected will optimize
the management of patients with nosocomial bloodstream infections.
Clinical Details
Official title: Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Study design: Time Perspective: Retrospective
Primary outcome: dead or alive
Detailed description:
The following information will be collected: age, sex, occupation, hospital location at the
time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of
outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy),
presence of invasive devices, receipt of antibiotics, including their type and whether they
were adequate for the resistance profile of the organism, prior positive microbiologic
cultures, time and location of positive cultures, underlying diseases and severity of
illness, presence of urinary or intravascular devices, recent immunomodulative therapies or
radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial
usage within 30 days of onset of the infection, microbiological data and resistance
patterns, choice of antibiotics once organism identified, bacteriological outcomes,
laboratory results, demographic information, medications, clinical outcome,gender, height,
weight, ethnicity, and past medical history. We will collect information retrospectively.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical information is collected by chart review of "case" and "control" patients.
A "case" patient is defined as follows:
- One or more blood cultures are positive for E. cloacae, E. aerogenes, C.
freundii, S. marcescens or M. morganii.
- The patient received piperacillin/tazobactam as the initial empiric therapy.
- The organism was susceptible to piperacillin/tazobactam.
- A "control" patient is defined as follows:
- One or more blood cultures are positive for E. cloacae, E. aerogenes, C.
freundii, S. marcescens or M. morganii.
- The patient received a carbapenem or fluoroquinolone antimicrobial as the
initial empiric therapy.
- The organism was susceptible to the empiric regimen.
Locations and Contacts
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, United States
Additional Information
Starting date: February 2007
Last updated: December 5, 2014
|
